CLIMB BIO INC (CLYM) Fundamental Analysis & Valuation

NASDAQ:CLYM • US28658R1068

7.33 USD
+0.08 (+1.1%)
At close: Mar 10, 2026
7.33 USD
0 (0%)
After Hours: 3/10/2026, 5:50:15 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CLYM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CLYM. CLYM was compared to 519 industry peers in the Biotechnology industry. While CLYM has a great health rating, there are worries on its profitability. CLYM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. CLYM Profitability Analysis

1.1 Basic Checks

  • In the past year CLYM has reported negative net income.
  • In the past year CLYM has reported a negative cash flow from operations.
  • In the past 5 years CLYM always reported negative net income.
  • In the past 5 years CLYM always reported negative operating cash flow.
CLYM Yearly Net Income VS EBIT VS OCF VS FCFCLYM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • The Return On Assets of CLYM (-27.84%) is better than 67.82% of its industry peers.
  • With a decent Return On Equity value of -28.67%, CLYM is doing good in the industry, outperforming 75.92% of the companies in the same industry.
Industry RankSector Rank
ROA -27.84%
ROE -28.67%
ROIC N/A
ROA(3y)-33.11%
ROA(5y)-44.53%
ROE(3y)-34.22%
ROE(5y)-48.01%
ROIC(3y)N/A
ROIC(5y)N/A
CLYM Yearly ROA, ROE, ROICCLYM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • CLYM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLYM Yearly Profit, Operating, Gross MarginsCLYM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CLYM Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for CLYM has been increased compared to 1 year ago.
  • Compared to 5 years ago, CLYM has more shares outstanding
  • CLYM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLYM Yearly Shares OutstandingCLYM Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLYM Yearly Total Debt VS Total AssetsCLYM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 53.41 indicates that CLYM is not in any danger for bankruptcy at the moment.
  • CLYM's Altman-Z score of 53.41 is amongst the best of the industry. CLYM outperforms 95.57% of its industry peers.
  • CLYM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 53.41
ROIC/WACCN/A
WACCN/A
CLYM Yearly LT Debt VS Equity VS FCFCLYM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • CLYM has a Current Ratio of 18.38. This indicates that CLYM is financially healthy and has no problem in meeting its short term obligations.
  • CLYM has a Current ratio of 18.38. This is amongst the best in the industry. CLYM outperforms 94.61% of its industry peers.
  • CLYM has a Quick Ratio of 18.38. This indicates that CLYM is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 18.38, CLYM belongs to the top of the industry, outperforming 94.61% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 18.38
Quick Ratio 18.38
CLYM Yearly Current Assets VS Current LiabilitesCLYM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. CLYM Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 64.84% over the past year.
EPS 1Y (TTM)64.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • CLYM is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -7.94% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y47.85%
EPS Next 2Y19.98%
EPS Next 3Y8.76%
EPS Next 5Y-7.94%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CLYM Yearly Revenue VS EstimatesCLYM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
CLYM Yearly EPS VS EstimatesCLYM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. CLYM Valuation Analysis

4.1 Price/Earnings Ratio

  • CLYM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CLYM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLYM Price Earnings VS Forward Price EarningsCLYM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLYM Per share dataCLYM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.98%
EPS Next 3Y8.76%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CLYM Dividend Analysis

5.1 Amount

  • No dividends for CLYM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CLYM Fundamentals: All Metrics, Ratios and Statistics

CLIMB BIO INC

NASDAQ:CLYM (3/10/2026, 5:50:15 PM)

After market: 7.33 0 (0%)

7.33

+0.08 (+1.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-09
Earnings (Next)N/A
Inst Owners53.67%
Inst Owner ChangeN/A
Ins Owners0.3%
Ins Owner Change-67.67%
Market Cap499.76M
Revenue(TTM)N/A
Net Income(TTM)-50.75M
Analysts88.57
Price Target11.66 (59.07%)
Short Float %2.84%
Short Ratio2.36
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.05%
Min EPS beat(2)-27%
Max EPS beat(2)31.11%
EPS beat(4)2
Avg EPS beat(4)-20.87%
Min EPS beat(4)-102.61%
Max EPS beat(4)31.11%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)20.3%
PT rev (3m)24.22%
EPS NQ rev (1m)-2.85%
EPS NQ rev (3m)-2.68%
EPS NY rev (1m)-0.55%
EPS NY rev (3m)0.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.82
P/tB 2.82
EV/EBITDA N/A
EPS(TTM)-0.76
EYN/A
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS0
BVpS2.6
TBVpS2.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -27.84%
ROE -28.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.11%
ROA(5y)-44.53%
ROE(3y)-34.22%
ROE(5y)-48.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.38
Quick Ratio 18.38
Altman-Z 53.41
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.8%
EPS Next Y47.85%
EPS Next 2Y19.98%
EPS Next 3Y8.76%
EPS Next 5Y-7.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-149.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.36%
EBIT Next 3Y-0.16%
EBIT Next 5Y-6.39%
FCF growth 1Y-58.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.43%
OCF growth 3YN/A
OCF growth 5YN/A

CLIMB BIO INC / CLYM FAQ

What is the fundamental rating for CLYM stock?

ChartMill assigns a fundamental rating of 3 / 10 to CLYM.


Can you provide the valuation status for CLIMB BIO INC?

ChartMill assigns a valuation rating of 0 / 10 to CLIMB BIO INC (CLYM). This can be considered as Overvalued.


How profitable is CLIMB BIO INC (CLYM) stock?

CLIMB BIO INC (CLYM) has a profitability rating of 1 / 10.


Can you provide the financial health for CLYM stock?

The financial health rating of CLIMB BIO INC (CLYM) is 8 / 10.


Can you provide the expected EPS growth for CLYM stock?

The Earnings per Share (EPS) of CLIMB BIO INC (CLYM) is expected to grow by 47.85% in the next year.